{
  "paper_id": "PMC6064585",
  "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6064585/",
  "figures": {
    "figure_1": {
      "figure_number": "Figure 1",
      "title": "Fig. 1.",
      "caption": "Design for the lead-in periods of the sequential add-on triple therapy studies. DAPA dapagliflozin, HbA1c glycated hemoglobin, IR immediate release, MET metformin, SAXA saxagliptin",
      "possible_urls": [
        [
          "original_src",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3303/6064585/ffe262b6cc1a/13300_2018_445_Fig1_HTML.jpg"
        ],
        [
          "large_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3303/6064585/ffe262b6cc1a/13300_2018_445_Fig1_HTML.jpg?maxwidth=2000"
        ],
        [
          "original_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3303/6064585/ffe262b6cc1a/13300_2018_445_Fig1_HTML.jpg?size=original"
        ],
        [
          "xlarge_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3303/6064585/ffe262b6cc1a/13300_2018_445_Fig1_HTML.jpg?maxwidth=4000"
        ]
      ],
      "figure_id": "Fig1",
      "is_table": false,
      "working_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3303/6064585/ffe262b6cc1a/13300_2018_445_Fig1_HTML.jpg",
      "download_success": true,
      "local_image_path": "./data/PMC6064585/images/figure_1.jpg",
      "final_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3303/6064585/ffe262b6cc1a/13300_2018_445_Fig1_HTML.jpg"
    },
    "figure_2": {
      "figure_number": "Figure 2",
      "title": "Fig. 2.",
      "caption": "HbA1c levels at lead-in baseline and the end of the lead-in period. Efficacy end points were assessed at week − 2 before randomization (treatment duration 14 weeks). Data are mean with SD shown as error bars. Mean change from baseline (95% CI) is shown above the bars. n is the number of patients with baseline and week − 2 results. CI confidence interval, DAPA dapagliflozin, HbA1c glycated hemoglobin, MET metformin, SAXA saxagliptin, SD standard deviation",
      "possible_urls": [
        [
          "original_src",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3303/6064585/51c2be4cd780/13300_2018_445_Fig2_HTML.jpg"
        ],
        [
          "large_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3303/6064585/51c2be4cd780/13300_2018_445_Fig2_HTML.jpg?maxwidth=2000"
        ],
        [
          "original_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3303/6064585/51c2be4cd780/13300_2018_445_Fig2_HTML.jpg?size=original"
        ],
        [
          "xlarge_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3303/6064585/51c2be4cd780/13300_2018_445_Fig2_HTML.jpg?maxwidth=4000"
        ]
      ],
      "figure_id": "Fig2",
      "is_table": false,
      "working_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3303/6064585/51c2be4cd780/13300_2018_445_Fig2_HTML.jpg",
      "download_success": true,
      "local_image_path": "./data/PMC6064585/images/figure_2.jpg",
      "final_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3303/6064585/51c2be4cd780/13300_2018_445_Fig2_HTML.jpg"
    }
  },
  "claims": [
    {
      "sentence": "Patients underwent 16 weeks of open-label treatment with the nearest multiple of metformin IR 500 mg to their usual dose and dapagliflozin 10 mg/day (Fig. 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Patients received the nearest multiple of metformin IR 500 mg to their usual dose and saxagliptin 5 mg/day for 16 weeks of open-label treatment (Fig. 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Patients underwent 16 weeks of open-label treatment with the nearest multiple of metformin IR 500 mg to their usual dose and dapagliflozin 10 mg/day (Fig. 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Patients received the nearest multiple of metformin IR 500 mg to their usual dose and saxagliptin 5 mg/day for 16 weeks of open-label treatment (Fig. 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Patients underwent 16 weeks of open-label treatment with the nearest multiple of metformin IR 500 mg to their usual dose and dapagliflozin 10 mg/day (Fig. 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Patients underwent 16 weeks of open-label treatment with the nearest multiple of metformin IR 500 mg to their usual dose and dapagliflozin 10 mg/day (Fig. 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Patients received the nearest multiple of metformin IR 500 mg to their usual dose and saxagliptin 5 mg/day for 16 weeks of open-label treatment (Fig. 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Patients received the nearest multiple of metformin IR 500 mg to their usual dose and saxagliptin 5 mg/day for 16 weeks of open-label treatment (Fig. 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Efficacy\nThe mean change in HbA1c [95% confidence interval (CI)] from lead-in baseline to end of lead-in was − 1.6% (− 1.7, − 1.5) [− 17.5 mmol/mol (− 18.6, − 16.4)] in patients in study 1 receiving dapagliflozin plus metformin therapy (Fig. 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "In patients in study 2 receiving saxagliptin plus metformin therapy, the mean change in HbA1c from lead-in baseline to end of lead-in was − 1.3% (− 1.5, − 1.2) [− 14.2 mmol/mol (− 16.4, − 13.1)] (Fig. 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "The mean change in HbA1c [95% confidence interval (CI)] from lead-in baseline to end of lead-in was − 1.6% (− 1.7, − 1.5) [− 17.5 mmol/mol (− 18.6, − 16.4)] in patients in study 1 receiving dapagliflozin plus metformin therapy (Fig. 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "In patients in study 2 receiving saxagliptin plus metformin therapy, the mean change in HbA1c from lead-in baseline to end of lead-in was − 1.3% (− 1.5, − 1.2) [− 14.2 mmol/mol (− 16.4, − 13.1)] (Fig. 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    }
  ],
  "extraction_stats": {
    "figures_count": 2,
    "claims_count": 12,
    "images_downloaded": 2,
    "tables_filtered": 166
  }
}